Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QVA149 versus tiotropium + formoterol in moderate to severe COPD
2011-004870-26Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing QVA149 with Tiotropium + formoterol (2 arms). Primary endpoint: Change from baseline in St George's Respiratory Questionnaire for COPD patients (SGRQ-C) total score at end of study. Started Feb 2012; status: completed.
02
Drugs
indacaterol + glycopyrroniumtiotropiumformoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2011-004870-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004870-26.